Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.

Pharmaceutical

Galectin Therapeutics

Galectin Therapeutics' headquarters in Norcross, GA, United States

Joel Lewis

Khurram Jamil

Marla Mills-Wilson

Jeff Katstra

Jack W. Callicutt

Gilbert F. Amelio

Richard E. Uihlein

James C. Czirr

Kary Eldred

Kevin D. Freeman

Richard A. Zordani

Elissa J. Schwartz

Marc Rubin

Gilbert S. Omenn

Harold H. Shlevin

Description

People (1)

Beth Knowles

Jobs